María José Safont

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

Medicine, Oncology, Surgery +17

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

Carlos Fernández-Martos, Xabier García‐Albéniz, Carles Pericay et al. · Annals of Oncology · 2015 · 357 citations · Full text

Medicine, Oncology, Surgery +16

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al. · The Oncologist · 2012 · 212 citations · Full text

Medicine, Oncology, Pharmacology +12

Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging–Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study

Miguel Nogué, Antonieta Salud, Pilar Vicente et al. · The Oncologist · 2011 · 155 citations · Full text

Medicine, Oncology, Surgery +17

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

Alfredo Carrato, Albert Abad, Bartomeu Massutí et al. · European Journal of Cancer · 2017 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +17